Buys | $0 | 0 | 0 |
Sells | $1,103,143 | 12 | 100 |
Schwendenman Andrew | Chief Accounting Officer | 0 | $0 | 1 | $14,868 | $-14,868 |
Sarchi Christopher | Chief Commercial Officer | 0 | $0 | 2 | $70,482 | $-70,482 |
Coffin Robert | director | 0 | $0 | 1 | $74,172 | $-74,172 |
Hill Emily Luisa | Chief Financial Officer | 0 | $0 | 1 | $90,989 | $-90,989 |
Love Colin | Chief Operating Officer | 0 | $0 | 1 | $113,969 | $-113,969 |
Xynos Konstantinos | Chief Medical Officer | 0 | $0 | 3 | $238,414 | $-238,414 |
Astley-Sparke Philip | Executive Chairman | 0 | $0 | 1 | $245,394 | $-245,394 |
Patel Sushil | Chief Executive Officer | 0 | $0 | 2 | $254,855 | $-254,855 |
Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing …
Over the last 12 months, insiders at Replimune Group, Inc. have bought $0 and sold $1.1M worth of Replimune Group, Inc. stock.
On average, over the past 5 years, insiders at Replimune Group, Inc. have bought $0 and sold $15.69M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 1,100,000 shares for transaction amount of $14.97M was made by Rhodes Jason P (director) on 2019‑11‑18.
2024-12-16 | Sale | Patel Sushil | Chief Executive Officer | 10,000 0.0132% | $12.42 | $124,200 | +0.64% | |
2024-11-18 | Sale | Xynos Konstantinos | Chief Medical Officer | 7,246 0.0106% | $10.78 | $78,112 | +17.36% | |
2024-11-18 | Sale | Sarchi Christopher | Chief Commercial Officer | 5,207 0.0076% | $10.78 | $56,131 | +17.36% | |
2024-08-16 | Sale | Hill Emily Luisa | Chief Financial Officer | 8,938 0.0137% | $10.18 | $90,989 | +18.30% | |
2024-06-07 | Sale | Xynos Konstantinos | Chief Medical Officer | 15,881 0.0245% | $7.50 | $119,108 | +43.42% | |
2024-05-16 | Sale | Coffin Robert | director | 11,464 0.0189% | $6.47 | $74,172 | +65.63% | |
2024-05-16 | Sale | Astley-Sparke Philip | Executive Chairman | 37,928 0.0626% | $6.47 | $245,394 | +65.63% | |
2024-05-16 | Sale | Love Colin | Chief Operating Officer | 17,615 0.0291% | $6.47 | $113,969 | +65.63% | |
2024-05-16 | Sale | Patel Sushil | Chief Executive Officer | 20,194 0.0333% | $6.47 | $130,655 | +65.63% | |
2024-05-16 | Sale | Xynos Konstantinos | Chief Medical Officer | 6,367 0.0105% | $6.47 | $41,194 | +65.63% | |
2024-05-16 | Sale | Sarchi Christopher | Chief Commercial Officer | 2,218 0.0037% | $6.47 | $14,350 | +65.63% | |
2024-05-16 | Sale | Schwendenman Andrew | Chief Accounting Officer | 2,298 0.0038% | $6.47 | $14,868 | +65.63% | |
2023-11-16 | Sale | Xynos Konstantinos | Chief Medical Officer | 7,313 0.0131% | $10.92 | $79,858 | -15.60% | |
2023-11-16 | Sale | Sarchi Christopher | Chief Commercial Officer | 5,255 0.0094% | $10.92 | $57,385 | -15.60% | |
2023-09-12 | Sale | Esposito Pamela | Chief Business Officer | 300 0.0005% | $20.00 | $6,000 | -54.46% | |
2023-09-11 | Sale | Esposito Pamela | Chief Business Officer | 5,358 0.0092% | $20.01 | $107,214 | -55.86% | |
2023-08-22 | Sale | Esposito Pamela | Chief Business Officer | 18,600 0.0315% | $20.01 | $372,186 | -56.41% | |
2023-08-11 | Sale | Esposito Pamela | Chief Business Officer | 1,400 0.0024% | $20.00 | $28,000 | -56.32% | |
2023-07-10 | Sale | Esposito Pamela | Chief Business Officer | 20,000 0.035% | $21.58 | $431,541 | -58.78% | |
2023-06-13 | Sale | Patel Sushil | Chief Strategy Officer | 5,698 0.0098% | $24.05 | $137,008 | -62.63% |
Omega Fund IV, L.P. | 4763380 6.185% | $55.52M | 2 | 20 | +27.98% | |
Slootweg Hugo Alexander | 4721449 6.1306% | $55.03M | 1 | 0 | <0.0001% | |
Forbion Capital Fund III Cooperatief U.A. | 10 percent owner | 4721449 6.1306% | $55.03M | 1 | 0 | <0.0001% |
Bain Capital Life Sciences Investors, LLC | 10 percent owner | 2838968 3.6863% | $33.09M | 1 | 0 | <0.0001% |
Rhodes Jason P | director | 946000 1.2283% | $11.03M | 1 | 11 | +63.12% |
$7,929,017 | 58 | 21.56% | $787.18M | |
$571,084,134 | 44 | 4.33% | $988.55M | |
$97,176 | 41 | 42.84% | $802.16M | |
$28,907,358 | 35 | 41.41% | $899.09M | |
$530,111,731 | 35 | 8.67% | $1.09B |
Increased Positions | 101 | +78.91% | 16M | +22.93% |
Decreased Positions | 50 | -39.06% | 6M | -8.91% |
New Positions | 35 | New | 6M | New |
Sold Out Positions | 19 | Sold Out | 1M | Sold Out |
Total Postitions | 179 | +39.84% | 80M | +14.02% |
Baker Bros. Advisors Lp | $140,055.00 | 14.35% | 11.05M | 0 | 0% | 2024-12-31 |
Price T Rowe Associates Inc /Md/ | $139,009.00 | 14.24% | 10.96M | +1M | +10.97% | 2024-12-31 |
Blackrock, Inc. | $70,582.00 | 7.23% | 5.57M | +94,833 | +1.73% | 2024-12-31 |
Redmile Group, Llc | $62,202.00 | 6.37% | 4.91M | +124,344 | +2.6% | 2024-12-31 |
Fcpm Iii Services B.V. | $50,348.00 | 5.16% | 3.97M | -895,781 | -18.41% | 2024-12-31 |
Vanguard Group Inc | $45,595.00 | 4.67% | 3.6M | +129,601 | +3.74% | 2024-12-31 |
Sofinnova Investments, Inc. | $39,936.00 | 4.09% | 3.15M | +3M | +6,442.69% | 2024-12-31 |
Tang Capital Management Llc | $34,236.00 | 3.51% | 2.7M | +2M | +125% | 2024-12-31 |
State Street Corp | $27,947.00 | 2.86% | 2.2M | -135,991 | -5.81% | 2024-12-31 |
Rtw Investments, Lp | $26,184.00 | 2.68% | 2.07M | +931,223 | +82.13% | 2024-12-31 |